Skip to main content

Table 4 Univariate analysis of TILs and the hematologic parameters associated with DFS in each of the breast cancer subtypes

From: The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer

Variable

Disease-free survival

HR+

HER2+

Triple-negative

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

AMC (high vs. low)

1.68 (0.52–5.45)

0.390

0.87 (0.27–2.74)

0.809

5.18 (1.08–24.94)

0.040*

ANC (high vs. low)

0.47 (0.15–1.43)

0.181

0.47 (0.15–1.47)

0.194

1.03 (0.28–3.85)

0.961

ALC (high vs. low)

0.26 (0.08–0.83)

0.024*

0.56 (0.18–1.77)

0.323

0.34 (0.07–1.63)

0.177

NLR (high vs. low)

1.06 (0.36–3.17)

0.911

0.82 (0.26–2.54)

0.729

2.54 (0.63–10.15)

0.188

LMR (high vs. low)

0.13 (0.03–0.59)

0.008*

1.14 (0.36–3.58)

0.828

0.23 (0.05–1.11)

0.067

PLR (high vs. low)

0.87 (0.29–2.59)

0.801

1.08 (0.34–3.42)

0.892

1.49 (0.40–5.56)

0.551

CD8 (high vs. low)

0.91 (0.30–2.71)

0.860

0.65 (0.19–2.19)

0.483

2.75 (0.69–10.99)

0.153

FOXP3 (high vs. low)

0.78 (0.26–2.34)

0.664

0.78 (0.25–2.43)

0.664

1.41 (0.38–5.27)

0.608

  1. AMC absolute monocyte count, ALC absolute lymphocyte count, ANC absolute neutrophil count, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, FOXP3 forkhead box protein 3, HER2+ hormone receptor positive or negative/ HER2-positive, HR+ hormone receptor positive/HER2-negative
  2. *p < 0.05